NCT04403191

Usage of Multiple Drugs in Treatment of Postoperative Vomiting After Laparoscopic Appendectomy

Comparative Study Between Ondansetron, Isopropyl Alcohol Inhalation and Super Hydration in Treatment of Postoperative Emesis After Laparoscopic Appendectomy

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 240 (actual)
• Sponsor: King Abdul Aziz Specialist Hospital · Network
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

To compare and evaluate the antiemetic effect and the safety of ondansetron, inhalational isopropyl alcohol and super hydration on adult patients after laparoscopic appendectomy.

Detailed description

This prospective double-blind study done on 240 patients admitted to surgical I.C.U after laparoscopic appendectomy. Those who had preoperative Koivuranta vomiting score of more than 3 enrolled in our study. Every group contains 80 patients. Patients of group A received ondansetron 4 mg intravenous immediately once reached to I.C.U and another same dose after 6 hours while patients of group B received isopropyl alcohol 70% inhalation every 15 min for 4 times then repeated after 6 hours. The last group C received intravenous normal saline at rate of 20 ml/kg over 30 minute and repeated by the same dose after 6 hours. The duration of the study was 24 hours post-operatively. As PONV is self-limited within 24 hours.

Conditions

• to Treat the Vomiting Frequently Occur Post-laparoscopic by Different Anti Emetic Drugs

Interventions

Type	Name	Description
DRUG	Ondansetron	ondansetron 4 mg intravenous immediately once reached to I.C.U and another same dose after 6 hours while patients of group
DRUG	isopropyl alcohol 70% inhalation	inhalation every 15 min for 4 times then repeated after 6 hours
PROCEDURE	laparoscopic appendectomy	all patients received post operatively after laparoscopic appenectomy

Timeline

• Start date: 2019-03-10
• Primary completion: 2020-02-04
• Completion: 2020-02-10
• First posted: 2020-05-27
• Last updated: 2020-05-28

Locations

1 site across 1 country: Saudi Arabia

Regulatory

• FDA-regulated drug study